BOS:TSXAirBoss of America Corporation Analysis
Data as of 2026-03-11 - not real-time
CA$6.49
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
AirBoss of America Corp. (BOS.TO) is trading in a bullish technical environment, with the 20‑day SMA comfortably above the 50‑day and 200‑day SMAs and a bullish MACD crossover. However, the RSI is well above 70, indicating the stock is overbought and may be vulnerable to a short‑term pullback. Volume is accelerating, and the price is perched near the upper end of its recent range, just below the identified resistance level. On the fundamentals side, the company posted modest revenue growth but remains loss‑making on a trailing basis, carries a high debt‑to‑equity ratio, and its dividend payout exceeds earnings, raising concerns about sustainability. The DCF model suggests a fair value far above the current price, yet analyst consensus only implies a modest upside of about 3 %, reflecting uncertainty around the upcoming Q4/ FY2025 earnings release scheduled for March 4, 2026.
Overall, the stock presents a mixed picture: strong short‑term technical momentum tempered by overbought conditions and weak profitability, while long‑term valuation appears attractive if the company can improve earnings and manage debt.
Overall, the stock presents a mixed picture: strong short‑term technical momentum tempered by overbought conditions and weak profitability, while long‑term valuation appears attractive if the company can improve earnings and manage debt.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Overbought RSI suggesting near‑term correction risk
- Upcoming earnings release could trigger volatility
- Technical bullishness but limited upside per analyst targets
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value substantially above current price
- Potential earnings improvement after board changes
- Attractive dividend yield if earnings stabilize
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to book and forward PE
- Strategic positioning in specialty chemicals and defense markets
- Long‑term upside potential if debt is reduced and profitability improves
Key Metrics & Analysis
Financial Health
Revenue Growth4.40%
Profit Margin-0.92%
P/E Ratio14.7
ROE-2.90%
ROA1.97%
Debt/Equity83.76
P/B Ratio1.0
Op. Cash FlowCA$32.4M
Free Cash FlowCA$25.1M
Technical Analysis
TrendBullish
RSI75.7
SupportCA$4.90
ResistanceCA$6.95
MA 20CA$5.84
MA 50CA$5.20
MA 200CA$4.89
MACDBullish
VolumeIncreasing
Fear & Greed Index78.16
Valuation
Fair ValueCA$12.02
Target PriceCA$6.69
Upside/Downside3.16%
GradeUndervalued
TypeBlend
Dividend Yield2.14%
Risk Assessment
Beta-0.09
Volatility38.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.